Document Detail


The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest.
MedLine Citation:
PMID:  15274302     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the present study, we examined the expression of peroxisome proliferator-activated receptor gamma (PPARgamma) and the growth-inhibitory effects of Troglitazone and Pioglitazone, selective ligands for PPARgamma, using a series of human esophageal carcinoma cell lines (TE-1, -3, -7, -8, -12 and -13). PPARgamma expression was detected in all six human esophageal carcinoma cell lines. The esophageal carcinoma cell line TE-13 showed marked growth inhibition in response to Troglitazone and Pioglitazone. Flow cytometry performed on TE-13 cells exposed to Troglitazone showed that the cell cycle was arrested at the G1-phase. This result was confirmed by the finding of reduced cyclin D and cyclin E expression by Western blot analysis. DNA ladder formation was also detected, as was the induction of apoptosis-related proteins. Our results suggested that Troglitazone inhibited the growth of human esophageal carcinoma cell lines via G1 arrest and apoptosis and that PPARgamma ligands should be considered as possible target molecules in the treatment of human esophageal carcinomas.
Authors:
Daisuke Fujii; Kazuhiro Yoshida; Kazuaki Tanabe; Jun Hihara; Tetsuya Toge
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  24     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2004 May-Jun
Date Detail:
Created Date:  2004-07-27     Completed Date:  2004-09-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  1409-16     Citation Subset:  IM    
Affiliation:
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. dai9318@hiroshima-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects*,  genetics
Blotting, Western
Cell Cycle / drug effects
Cell Cycle Proteins / biosynthesis
Cell Division / drug effects
Cell Line, Tumor
Chromans / pharmacology*
Esophageal Neoplasms / drug therapy*,  genetics,  metabolism,  pathology
Gene Expression Regulation, Neoplastic / drug effects
Humans
Ligands
Receptors, Cytoplasmic and Nuclear / biosynthesis*,  metabolism
Thiazolidinediones / pharmacology*
Transcription Factors / biosynthesis*,  metabolism
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Cell Cycle Proteins; 0/Chromans; 0/Ligands; 0/Receptors, Cytoplasmic and Nuclear; 0/Thiazolidinediones; 0/Transcription Factors; 111025-46-8/pioglitazone; 97322-87-7/troglitazone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Selenium compounds regulate p53 by common and distinctive mechanisms.
Next Document:  Analysis of Sciellin (SCEL) as a candidate gene in esophageal squamous cell carcinoma.